Molecular imaging by cardiovascular MR.
Do molecularly-targeted contrast agents have what it takes to usher in a paradigm shift as to how we will image cardiovascular disease in the near future? Moreover, are non-invasive vulnerable plaque detection and preemptive treatments with these novel nanoparticulate agents within reach for clinical applications? In this article, we attempt to make a compelling case for how the advent of molecularly-targeted nanoparticle technology may change the way we detect atherosclerotic lesions, determine their clinical significance and even provide non-invasive treatments. Focusing on imaging with cardiovascular MR, an overview of the latest developments in this rapidly evolving field of so-called "intelligent" contrast agents that are able to interrogate the vascular wall and various complementary advanced imaging technologies are presented.
Cyrus
Tillmann
T
Division of Cardiology, Washington University School of Medicine, St. Louis, MO 63108, USA.
Lanza
Gregory M
GM
Wickline
Samuel A
SA
D000818:Animals; D017209:Apoptosis; D050197:Atherosclerosis / Q000175:diagnosis* / Q000517:prevention & control; D003287:Contrast Media / Q000494:pharmacology*; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D053758:Nanoparticles; D009389:Neovascularization, Pathologic / Q000175:diagnosis / Q000517:prevention & control
D003287:Contrast Media